Kudura, K.; Ritz, N.; Templeton, A.J.; Kutzker, T.; Foerster, R.; Antwi, K.; Kreissl, M.C.; Hoffmann, M.H.K.
Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. J. Clin. Med. 2023, 12, 3725.
https://doi.org/10.3390/jcm12113725
AMA Style
Kudura K, Ritz N, Templeton AJ, Kutzker T, Foerster R, Antwi K, Kreissl MC, Hoffmann MHK.
Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. Journal of Clinical Medicine. 2023; 12(11):3725.
https://doi.org/10.3390/jcm12113725
Chicago/Turabian Style
Kudura, Ken, Nando Ritz, Arnoud J. Templeton, Tim Kutzker, Robert Foerster, Kwadwo Antwi, Michael C. Kreissl, and Martin H. K. Hoffmann.
2023. "Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition" Journal of Clinical Medicine 12, no. 11: 3725.
https://doi.org/10.3390/jcm12113725
APA Style
Kudura, K., Ritz, N., Templeton, A. J., Kutzker, T., Foerster, R., Antwi, K., Kreissl, M. C., & Hoffmann, M. H. K.
(2023). Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. Journal of Clinical Medicine, 12(11), 3725.
https://doi.org/10.3390/jcm12113725
